Expression of lactate transporters MCT1, MCT2, MCT4 and the ancillary protein CD147 in horse muscle and red blood cells

Monocarboxylate transporters (MCTs) transport lactate and protons across cell membranes. During intense exercise, lactate and protons accumulate in the exercising muscle and are transported to the plasma. In the horse, MCTs are responsible for the majority of lactate and proton removal from exercising muscle, and are therefore also the main mechanism to hinder the decline in pH in muscle cells. Two isoforms, MCT1 and MCT4, which need an ancillary protein CD147, are expressed in equine muscle. In the horse, as in other species, MCT1 is predominantly expressed in oxidative fibres, where its likely role is to transport lactate into the fibre to be used as a fuel at rest and during light work, and to remove lactate during intensive exercise when anaerobic energy production is needed. The expression of CD147 follows the fibre type distribution of MCT1. These proteins were detected in both the cytoplasm and sarcolemma of muscle cells in the horse breeds studied: Standardbred and Coldblood trotters. In humans, training increases the expression of both MCT1 and MCT4. In this study, the proportion of oxidative fibres in the muscle of Norwegian-Swedish Coldblood trotters increased with training. Simultaneously, the expression of MCT1 and CD147, measured immunohistochemically, seemed to increase more in the cytoplasm of oxidative fibres than in the fast fibre type IIB. Horse MCT4 antibody failed to work in immunohistochemistry. In the future, a quantitative method should be introduced to examine the effect of training on muscle MCT expression in the horse. Lactate can be taken up from plasma by red blood cells (RBCs). In horses, two isoforms, MCT1 and MCT2, and the ancillary protein CD147 are expressed in RBC membranes. The horse is the only species studied in which RBCs have been found to express MCT2, and the physiological role of this protein in RBCs is unknown. The majority of horses express all three proteins, but 10-20% of horses express little or no MCT1 or CD147. This leads to large interindividual variation in the capacity to transport lactate into RBCs. Here, the expression level of MCT1 and CD147 was bimodally distributed in three studied horse breeds: Finnhorse, Standardbred and Thoroughbred. The level of MCT2 expression was distributed unimodally. The expression level of lactate transporters could not be linked to performance markers in Thoroughbred racehorses. In the future, better performance indexes should be developed to better enable the assessment of whether the level of MCT expression affects athletic performance. In human subjects, several mutations in MCT1 have been shown to cause decreased lactate transport activity in muscle and signs of myopathy. In the horse, two amino acid sequence variations, one of which was novel, were detected in MCT1 (V432I and K457Q). The mutations found in horses were in different areas compared to mutations found in humans. One mutation (M125V) was detected in CD147. The mutations found could not be linked with exercise-induced myopathy. MCT4 cDNA was sequenced for the first time in the horse, but no mutations could be detected in this protein.

Two levels of MCT1 and CD147 expression in the equine red blood cells and muscle

Monocarboxylate transporters (MCTs), especially the isoforms MCT1 - MCT4, cotransport lactate and protons across the cell membranes. They are thus essential for pH regulation and homeostasis in glycolytic cells such as red blood cells (RBCs), and skeletal muscle cells during intense exercise. In 70% of the Standardbred horses the lactate transport activity (TA) in RBCs is high and transport is mediated mainly by MCTs. In the rest 30% of the Standardbreds MCT mediated transport route is not active and the TA is low. MCTs need an ancillary protein for their proper localization and functioning in the plasma membrane. The ancillary protein for MCT1 and MCT4 is a member of immunoglobulin superfamily, CD147. Here we determined the expression of MCT isoforms and CD147 in equine RBCs and gluteal muscle. We sequenced the cDNA of horse MCT1 and CD147 to achieve horse-specific antibodies and to reveal sequence variations that may affect the TA of RBCs. The amount of MCT1 and CD147 mRNA in muscle were also studied. ---- In all, 73 horses representing different breeds were used. Blood samples were drawn from the jugular vein and muscle samples were taken either from gluteal muscle using biopsy needle or during castration from expendable cremaster muscle. The TA of RBCs was studied using radiolabeled lactate and the amount of MCT isoforms and CD147 in the plasma membranes using Western blotting. The level of mRNA in muscle cells was determined using qPCR. Isoforms MCT1 and MCT2 were found in the RBCs and isoforms MCT1 and MCT4 in the muscle cells of horses. The TA of RBCs was dependent on the expression of CD147 and MCT1 in the plasma membrane. Sequence variations were found in the cDNA of both MCT1 and CD147, but they did not explain the inactivity of MCT1 mediated transport route. The single nucleotide polymorphism (SNP) Met125Val in CD147 that existed parallel with an SNP in 3´-untranslated region explained, however, attenuation in CD147 expression in Standardbreds. A single mutation Ile51Val also decreased the expression of CD147 in one Warmblood. The MCT1 and CD147 mRNA concentrations in the gluteal muscle were higher in horses with higher MCT1 and CD147 expression in RBCs and lower in horses with minor expression of CD147 and MCT1. This suggests that the bimodal distribution of TA is due to differences in transcriptional regulation that is functioning in parallel in MCT1 and CD147 gene.

MCT1-, MCT4- ja CD147-proteiinit kehittyvässä kilin pötsissä

Nuoren märehtijän alkaessa syödä kiinteää ravintoa, etumahojen suhteellinen osuus mahoista kasvaa ja niiden seinämän epiteeli alkaa kehittyä mahdollistaakseen ravintoaineiden tehokkaan imeytymisen. Märehtijöillä rehun hiilihydraatit hajoavat pötsissä haihtuviksi rasvahapoiksi, ja monokarboksylaattikuljettajien uskotaan avustavan haihtuvien rasvahappojen imeytymisessä pötsin seinämän läpi. Pötsin seinämässä on todettu olevan ainakin MCT1- ja MCT4 –isoformeja. Nämä tarvitsevat toimiakseen CD147 -proteiinin (myös OX-47, EMMPRIN, HT7 ja basigin), joka on on glykosyloitu integraalinen membraaniproteiini. Tämän tutkimuksen tarkoituksena oli selvittää MCT1-, MCT4- ja CD147 –proteiinien muutoksia pötsin toiminnan kehittymisen aikana. Toisena tavoitteena oli selvittää, voidaanko näytteenä käyttää solukalvojen sijasta pötsin seinämästä tehtyä homogenaattia. Tutkimuksessa käytettiin eri ikäisinä lopetetuista kileistä kerättyjä näytteitä. Kilejä oli yhteensä 31, joista 7 oli 3-21 tunnin ikäisiä, 7 viikon ikäisiä, 7 kahden viikon ikäisiä, 1 kolmen viikon ikäinen, 2 neljän viikon ikäistä, sekä 7 kahdeksan viikon ikäistä. Pötsin seinämästä otettiin näyte, josta valmistettiin homogenaatti ja eristettiin solukalvot eli membraanit. Pötsinäytteistä löydettiin MCT1- ja CD147 –proteiineja, mutta MCT4- isoformia ei ollut havaittavissa. Membraaninäytteissä havaittiin MCT1 -isoformin pitoisuuksien kasvavan iän mukana, paitsi kahdeksan viikon ikäisillä kileillä, joilla MCT1 –isoformin määrät vähenivät merkitsevästi. CD147 –proteiinia oli havaittavissa jo vastasyntyneiden kilien pötsinäytteissä. Membraaninäytteissä CD147 -proteiinin määrä kasvoi lineaarisesti iän mukana ja CD147- proteiinin ja MCT1 –isoformin välillä havaittiin tilastollisesti merkitsevä korrelaatio. Homogenaattinäytteissä MCT1 -isoformin määrissä ei havaittu korrelaatiota iän kanssa. MCT1- ja MCT4 -isoformien solukalvolle siirtymisessä avustavan CD147 –proteiinin ei myöskään havaittu korreloivan koe-eläinten iän tai MCT1 -isoformin kanssa. Membraani- ja homogenaattinäytteistä mitattujen MCT1- ja CD147 -määrien välillä ei ollut korrelaatiota. Haihtuvien rasvahappojen muodostus alkaa, kun eläin aloittaa kiinteän ravinnon syömisen. Tästä seuraa, että haihtuvia rasvahappoja kuljettavia proteiineja tarvitaan epiteelisolujen pinnalle. Tutkimuksessa havaittiin haihtuvia rasvahappoja kuljettavan MCT1 –proteiinin ja sen apuproteiinien määrän lisääntyminen iän myötä. N. 8-11 viikon iässä, jolloin pötsin toiminta on kehittynyt aikuisen eläimen tasolle, MCT1 –proteiinin määrä oli merkitsevästi vähäisempi kuin 4 viikon iässä. Tulosten perusteella homogenaatti ei ole hyvä tapa mitata membraaniproteiinien määrää.

Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization

Background: Soft tissue sarcomas (STSs) are a group of neoplasms, which, despite current therapeutic advances, still confer a poor outcome to half of the patients. As other solid tumors, STSs exhibit high glucose consumption rates, associated with worse prognosis and therapeutic response. As highly glycolytic tumors, we hypothesized that sarcomas should present an increased expression of lactate transporters (MCTs).Methods: Immunohistochemical expression of MCT1, MCT2, MCT4 and CD147 was assessed in a series of 86 STSs and the expression profiles were associated with patients' clinical-pathological parameters.Results: MCT1, MCT4 and CD147 were mainly observed in the plasma membrane of cancer cells (around 60% for MCTs and 40% for CD147), while MCT2 was conspicuously found in the cytoplasm (94.2%). Importantly, we observed MCT1 nuclear expression (32.6%). MCT1 and MCT4, alone or co-expressed with CD147 in the plasma membrane, were associated with poor prognostic variables including high tumor grade, disease progression and shorter overall survival. Conversely, we found MCT1 nuclear expression to be associated with low grade tumors and longer overall survival.Conclusions: The present work represents the first report of MCTs characterization in STSs. We showed the original finding of MCT1 expression in the nucleus. Importantly, opposite biological roles should be behind the dual sub-cellular localization of MCT1, as plasma membrane expression of MCT1 is associated with worse patients' prognosis, while nuclear expression is associated with better prognosis.

Expressão do transportador de monocarboxilato MCT1 e sua proteína auxiliar CD 147 em hemácias de equinos de salto

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs)

Monocarboxylate transporters (MCTs) have been described to play an important role in cancer, but to date there are no reports on the significance of MCT expression in gastrointestinal stromal tumors (GISTs). The aim of the present work was to assess the value of MCT expression, as well as co-expression with the MCT chaperone CD147 in GISTs and evaluate their clinical-pathological significance. We analyzed the immunohistochemical expression of MCT1, MCT2, MCT4 and CD147 in a series of 64 GISTs molecularly characterized for KIT, PDGFRA and BRAF mutations. MCT1, MCT2 and MCT4 were highly expressed in GISTs. CD147 expression was associated with mutated KIT (p = 0.039), as well as a progressive increase in Fletcher's Risk of Malignancy (p = 0.020). Importantly, co-expression of MCT1 with CD147 was associated with low patient's overall survival (p = 0.037). These findings suggest that co-expression of MCT1 with its chaperone CD147 is involved in GISTs aggressiveness, pointing to a contribution of cancer cell metabolic adaptations in GIST development and/or progression.

Influencia de varios polimorfismos en los genes MCT1 y CPT2 sobre el metabolismo energético durante el ejercicio

Las diferencias individuales ante cualquier estímulo son parte de la condición humana, y reflejan nuestra diversidad genética, así como la influencia del entorno. Conocer el papel que juegan las variaciones genéticas o polimorfismos, es vital para entender de forma integral la respuesta del organismo al ejercicio. Por tanto, el presente trabajo tiene como objetivo fundamental definir el posible rol de tres variantes genéticas en el metabolismo energético durante la realización de ejercicio físico. Más concretamente, los objetivos principales son, por un lado, observar si existen diferencias en la respuesta láctica en sangre capilar y venosa en función del polimorfismo A1470T del gen del Transportador de Monocarboxilatos 1 (MCT1) (rs1049434). Por otro lado, el segundo objetivo es estudiar si presencia del polimorfismo del gen MCT1 determina parcialmente la máxima concentración de lactato en sangre venosa alcanzada durante diferentes protocolos de circuitos de fuerza. Por último, los objetivos tercero y cuarto se centran en analizar si existen diferencias en las ratios de acilcarnitinas en sangre, que reflejan la actividad de la Carnitina Palmitoiltransferasa II (CPTII), en función de los polimorfismo Val368Ile (rs1799821) y Met647Val (rs1799822) del gen de la CPTII (CPT2) durante la realización de una sesión de Circuito Mixto de musculación-aeróbico. Para la consecución de estos objetivos se realizaron dos estudios (Piloto y General). En el primero de ellos (Estudio Piloto) 10 hombres estudiantes de la Licenciatura en Ciencias de la Actividad Física y del Deporte (CCAFD) realizaron 6 sesiones de fuerza en circuito. En días no continuados y a una intensidad diferente (30%, 40%, 50%, 60%, 70% u 80% de la 15 repetición máxima, 15RM), los sujetos ejecutaron tres vueltas a un mismo circuito de 8 ejercicios. A lo largo de la sesión se tomaron muestras de sangre capilar para el análisis de la concentración de lactato. En el Estudio General, 15 hombres y 14 mujeres estudiantes de la Licenciatura en CCAFD realizaron 3 protocolos de fuerza en circuito, al 70% de la 15 RM y al 70% de la reserva de la frecuencia cardiaca. Cada día ejecutaron un protocolo diferente: Circuito de Máquinas, Circuito de Peso Libre o Circuito Mixto de musculación- aeróbico, completando en cada uno tres vueltas. Durante cada una de las sesiones se extrajeron muestras de sangre venosa para el análisis de la concentración de lactato y del perfil de acilcarnitinas. Los resultados del presente trabajo evidencian que los sujetos portadores del polimorfismo A1470T del MCT1 (genotipos AT y TT) tienen un comportamiento de lactato diferente que los sujetos no portadores (genotipo AA) cuando se someten a diferentes circuitos de fuerza. En el Estudio Piloto los portadores tuvieron mayor pendiente de acumulación de lactato capilar a la intensidad del 80% de la 15RM, mientras que en el Estudio General los sujetos homocigotos para la variante genética (TT) registraron menores concentraciones de lactato venoso que los homocigotos normales (AA) durante el Circuito de Máquinas. No podemos concluir si esta diferencia de resultados se deriva del tipo de sangre analizada (capilar VS. venosa), de la existencia de un efecto umbral para el transportador o de una bidireccionalidad del MCT1, aunque la hipótesis de bidireccionalidad parece la más integradora. En el grupo de mujeres, no se observó un patrón claro de diferencias entre grupos genéticos por lo que no podemos concluir si el polimorfismo tiene efecto o no en este sexo. En el estudio 2 del Estudio General, la inclusión la variante del MCT1 como variable predictora cuando las variables dependientes fueron la máxima concentración de lactato venosa en los tres protocolos en conjunto, o la máxima concentración venosa durante el Circuito de Máquinas, confirma su influencia en los entrenamientos con elevada producción de lactato. No obstante, en los entrenamientos con concentraciones de lactato más bajas, parece que existen factores más determinantes para la máxima concentración que el polimorfismo del MCT1. Por último, los resultados del tercer estudio del Estudio General, aunque preliminares, sugieren que la presencia de las variantes polimórficas del CPT2 podría influir sobre el transporte de los ácidos grasos durante la realización de actividad física, particularmente en hombres. Aún así, son necesarios más estudios para confirmar, especialmente en mujeres, la influencia de ambos polimorfismos en la actividad de la CPTII.

MCT1 T1470A polymorphism influences adherence to strength training in overweight and obese men following a weight loss program

The monocarboxylate transporter (MCT) family member MCT1 transports lactate into and out of myocytes. Oxidative cells import lactate through MCT1 as a substrate, being the role of MCT1 in glycolysis-derived lactate efflux less clear. MCT1 T1470A polymorphism (rs1049434), which has been related with lactate metabolism and sports specialty 1, 2, could be an influencing factor for exercise adherence. Therefore the aim of this study was to relate the adherence to different training modalities with the T1470A MCT1 polymorphism in overweight and obese men following a weight loss program (WLP).

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression

Background: The aim of this study is to seek an association between markers of metastatic potential, drug resistance-related protein and monocarboxylate transporters in prostate cancer (CaP). Methods: We evaluated the expression of invasive markers (CD147, CD44v3-10), drug-resistance protein (MDR1) and monocarboxylate transporters (MCT1 and MCT4) in CaP metastatic cell lines and CaP tissue microarrays (n=140) by immunostaining. The co-expression of CD147 and CD44v3-10 with that of MDR1, MCT1 and MCT4 in CaP cell lines was evaluated using confocal microscopy. The relationship between the expression of CD147 and CD44v3-10 and the sensitivity (IC50) to docetaxel in CaP cell lines was assessed using MTT assay. The relationship between expression of CD44v3-10, MDR1 and MCT4 and various clinicopathological CaP progression parameters was examined. Results: CD147 and CD44v3-10 were co-expressed with MDR1, MCT1 and MCT4 in primary and metastatic CaP cells. Both CD147 and CD44v3-10 expression levels were inversely related to docetaxel sensitivity (IC50) in metastatic CaP cell lines. Overexpression of CD44v3-10, MDR1 and MCT4 was found in most primary CaP tissues, and was significantly associated with CaP progression. Conclusions: Our results suggest that the overexpression of CD147, CD44v3-10, MDR1 and MCT4 is associated with CaP progression. Expression of both CD147 and CD44v3-10 is correlated with drug resistance during CaP metastasis and could be a useful potential therapeutic target in advanced disease.

Brain-derived neurotrophic factor enhances the hippocampal expression of key postsynaptic proteins in vivo including the monocarboxylate transporter MCT2.

Brain-derived neurotrophic factor (BDNF) promotes synaptic plasticity via an enhancement in expression of specific synaptic proteins. Recent results suggest that the neuronal monocarboxylate transporter MCT2 is a postsynaptic protein critically involved in synaptic plasticity and long-term memory. To investigate in vivo whether BDNF can modulate the expression of MCT2 as well as other proteins involved in synaptic plasticity, acute injection of BDNF was performed in mouse dorsal hippocampal CA1 area. Using immunohistochemistry, it was found that MCT2 expression was enhanced in part of the CA1 area and in the dentate gyrus 6 h after a single intrahippocampal injection of BDNF. Similarly, expression of the immediate early genes Arc and Zif268 was enhanced in the same hippocampal areas, in accordance with their role in synaptic plasticity. Immunoblot analysis confirmed the significant enhancement in MCT2 protein expression. In contrast, no changes were observed for the glial monocarboxylate transporters MCT1 and MCT4. When other synaptic proteins were investigated, it was found that postsynaptic density 95 (PSD95) and glutamate receptor 2 (GluR2) protein levels were significantly enhanced while no effect could be detected for synaptophysin, synaptosomal-associated protein 25 (SNAP25), αCaMKII and GluR1. These results demonstrate that MCT2 expression can be upregulated together with other key postsynaptic proteins in vivo under conditions related to synaptic plasticity, further suggesting the importance of energetics for memory formation.

Oligodendroglia metabolically support axons and contribute to neurodegeneration.

Oligodendroglia support axon survival and function through mechanisms independent of myelination, and their dysfunction leads to axon degeneration in several diseases. The cause of this degeneration has not been determined, but lack of energy metabolites such as glucose or lactate has been proposed. Lactate is transported exclusively by monocarboxylate transporters, and changes to these transporters alter lactate production and use. Here we show that the most abundant lactate transporter in the central nervous system, monocarboxylate transporter 1 (MCT1, also known as SLC16A1), is highly enriched within oligodendroglia and that disruption of this transporter produces axon damage and neuron loss in animal and cell culture models. In addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 in pathogenesis. The role of oligodendroglia in axon function and neuron survival has been elusive; this study defines a new fundamental mechanism by which oligodendroglia support neurons and axons.

Temporal changes in mRNA expression of the brain nutrient transporters in the lithium-pilocarpine model of epilepsy in the immature and adult rat.

The lithium-pilocarpine model mimics most features of human temporal lobe epilepsy. Following our prior studies of cerebral metabolic changes, here we explored the expression of transporters for glucose (GLUT1 and GLUT3) and monocarboxylates (MCT1 and MCT2) during and after status epilepticus (SE) induced by lithium-pilocarpine in PN10, PN21, and adult rats. In situ hybridization was used to study the expression of transporter mRNAs during the acute phase (1, 4, 12 and 24h of SE), the latent phase, and the early and late chronic phases. During SE, GLUT1 expression was increased throughout the brain between 1 and 12h of SE, more strongly in adult rats; GLUT3 increased only transiently, at 1 and 4h of SE and mainly in PN10 rats; MCT1 was increased at all ages but 5-10-fold more in adult than in immature rats; MCT2 expression increased mainly in adult rats. At all ages, MCT1 and MCT2 up-regulation was limited to the circuit of seizures while GLUT1 and GLUT3 changes were more widespread. During the latent and chronic phases, the expression of nutrient transporters was normal in PN10 rats. In PN21 rats, GLUT1 was up-regulated in all brain regions. In contrast, in adult rats GLUT1 expression was down-regulated in the piriform cortex, hilus and CA1 as a result of extensive neuronal death. The changes in nutrient transporter expression reported here further support previous findings in other experimental models demonstrating rapid transcriptional responses to marked changes in cerebral energetic/glucose demand.

Oxygen tension controls the expression of the monocarboxylate transporter MCT4 in cultured mouse cortical astrocytes via a hypoxia-inducible factor-1α-mediated transcriptional regulation.

The monocarboxylate transporter MCT4 is a high capacity carrier important for lactate release from highly glycolytic cells. In the central nervous system, MCT4 is predominantly expressed by astrocytes. Surprisingly, MCT4 expression in cultured astrocytes is low, suggesting that a physiological characteristic, not met in culture conditions, is necessary. Here we demonstrate that reducing oxygen concentration from 21% to either 1 or 0% restored in a concentration-dependent manner the expression of MCT4 at the mRNA and protein levels in cultured astrocytes. This effect was specific for MCT4 since the expression of MCT1, the other astrocytic monocarboxylate transporter present in vitro, was not altered in such conditions. MCT4 expression was shown to be controlled by the transcription factor hypoxia-inducible factor-1α (HIF-1α) since under low oxygen levels, transfecting astrocyte cultures with a siRNA targeting HIF-1α largely prevented MCT4 induction. Moreover, the prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG) induced MCT4 expression in astrocytes cultured in presence of 21% oxygen. In parallel, glycolytic activity was enhanced by exposure to 1% oxygen as demonstrated by the increased lactate release, an effect dependent on MCT4 expression. Finally, MCT4 expression was found to be necessary for astrocyte survival when exposed for a prolonged period to 1% oxygen. These data suggest that a major determinant of astrocyte MCT4 expression in vivo is likely the oxygen tension. This could be relevant in areas of high neuronal activity and oxygen consumption, favouring astrocytic lactate supply to neurons. Moreover, it could also play an important role for neuronal recovery after an ischemic episode.

Monocarboxylate transporters: new players in body weight regulation.

Over the last two decades, several genes have been identified that appear to play a role in the regulation of energy homeostasis and body weight. For a small subset of them, a reduction or an absence of expression confers a resistance to the development of obesity. Recently, a knockin mouse for a member of the monocarboxylate transporter (MCT) family, MCT1, was demonstrated to exhibit a typical phenotype of resistance to diet-induced obesity and a protection from its associated metabolic perturbations. Such findings point out at MCTs as putatively new therapeutic targets in the context of obesity. Here, we will review what is known about MCTs and their possible metabolic roles in different organs and tissues. Based on the description of the phenotype of the MCT1 knockin mouse, we will also provide some insights about their putative roles in weight gain regulation.